Neuropeptides and Social Behavior

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Social Psychology
Interventions
DRUG

Intranasal oxytocin

Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).

DRUG

Intranasal vasopressin

Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).

DRUG

Intranasal placebo

Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).

Trial Locations (1)

90095-1563

UCLA Department of Psychology, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT01680718 - Neuropeptides and Social Behavior | Biotech Hunter | Biotech Hunter